Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Aurora Cannabis Announces Fiscal 2025 First Quarter Results and Delivers Positive Free Cash Flow

      Aurora Cannabis Inc. Logo (CNW Group/Aurora Cannabis Inc.)

      News provided by

      Aurora Cannabis Inc.

      Aug 07, 2024, 07:00 ET

      Share this article

      Share this article


      • Delivers Positive Free Cash Flow1 of $6.5 Million
      • Increases Total Quarterly Net Revenue1 by 12% YoY to $83.4 Million, Record Net Revenue1 of $47.2 Million in Global Medical Cannabis 
      • Generates Adjusted EBITDA1 of $4.9 Million, a YoY increase of 87%
      • Ends the Fiscal Quarter with a Debt-Free Cannabis Business2 and a Cash Position of ~$182 Million

      EDMONTON, AB, Aug. 7, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the first quarter fiscal 2025.

      "This was a milestone quarter for Aurora, as we delivered strong net revenue1 growth, a substantial increase in adjusted EBITDA1, and positive free cash flow1. Our impressive performance was driven by record net revenue1 in the rapidly growing global medical cannabis segment, and we look forward to building on our achievements in key markets such as Germany, Australia, and the UK throughout fiscal 2025 and beyond. The quarter was further supported by a record contribution from our Bevo plant propagation business, underscoring the strength of our diversified business model," said Chief Executive Officer Miguel Martin.

      "The progress we made during the quarter sets a strong foundation for the rest of the fiscal year, and with our continued commitment to operational excellence and strategic growth, we are well-positioned to sustain this positive momentum. Our growth in global medical, the highest margin cannabis segment, alongside our strong balance sheet and ongoing fiscal discipline, are pivotal as we build on our achievement with respect to positive free cash flow," Mr. Martin concluded.


      1 This press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. See "Non-GAAP Measures" below for reconciliations of non-GAAP financial measures to GAAP financial measures.

      2  Aurora's only remaining  debt is non-recourse debt of $52.4 million relating to Bevo Farms Ltd as detailed in the FY2025 Q1 Financial Statements

      First Quarter 2025 Highlights

      (Unless otherwise stated, comparisons are made between fiscal Q1 2025, Q4 2024, and Q1 2024 results and are in Canadian dollars)

      Consolidated Revenue and Adjusted Gross Profit:
      Total net revenue1 was $83.4 million, as compared to $74.7 million in the prior year period. The 12% increase from the prior period was mainly due to 13% growth in our global medical cannabis business and 16% growth in our plant propagation business, slightly offset by lower quarterly revenue in our consumer cannabis.

      Consolidated adjusted gross margin before fair value adjustments1 was 43% in Q1 2025 and 44% in the prior year quarter. Adjusted gross profit before FV adjustments1 was $36.0 million in Q1 2025 vs $32.6 million in the prior year quarter, an increase of 10%.

      Medical Cannabis:
      Medical cannabis net revenue1 was $47.2 million, a 13% increase from the prior year quarter, delivering 57% of Aurora's Q1 2025 consolidated net revenue1 and 91% of adjusted gross profit before fair value adjustments1.

      The increase in net revenue1 of $5.6 million was primarily due to higher sales to Australia and a steady increase in sales in Canada to insurance covered patients and larger basket sizes.

      Adjusted gross margin before fair value adjustments1 on medical cannabis net revenue reached 69% for the three months ended June 30, 2024, compared to 61% in the prior year quarter. Our target range is 60% and above. The adjusted gross margins before fair value adjustments improved through sustainable cost reductions, higher selling prices in Australia, and improved efficiency in production operations, including sourcing for Europe from Canada due to the closure of the Aurora Nordic production facility.

      Consumer Cannabis:
      Aurora's consumer cannabis net revenue1 was $11.5 million, a 10% decrease compared to $12.8 million in the prior year quarter. The decrease was due to our decision to prioritize the supply of our GMP manufactured products to our high margin international business rather than the consumer business, which offers lower margins.

      Adjusted gross margin before fair value adjustments1 on consumer cannabis net revenue1 was 24%, decreasing from 26% compared to the prior year quarter. The decrease from the prior year comparative quarter is largely due to higher margin product sales.

      Plant Propagation:
      Plant propagation net revenue1 was wholly comprised of the Bevo business, and contributed $23.1 million of net revenue1, a 16% increase compared to $19.9 million in the prior year quarter. The increase was a result of organic growth and increased product offerings. Historically, approximately 65-75% of plant propagation revenue and up to 80% of EBITDA has been earned in the first half of the calendar year.

      Adjusted gross margin before fair value adjustments1 on plant propagation revenue was 18% for Q1 2025 and 22% for the prior year quarter. The fluctuations in the plant propagation adjusted gross margin before fair value adjustments is due to changes in product mix and a prolonged Spring season in the current quarter.

      Selling, General and Administrative ("SG&A"):
      Adjusted SG&A1 was $31.4 million in Q1 2025, which excludes $4.9 million of business transformation costs. Adjusted SG&A1 is likely to remain above our previous target of $30 million due to the incremental SG&A following the acquisition of MedReleaf Australia.

      Adjusted R&D1, was $1.0 million in Q1 2025, which is relatively consistent as compared to the prior year quarter at $1.1 million. Our investment in R&D and product innovation is partly opportunistic, as such these costs will vary quarter over quarter and year over year.

      Net Income (Loss):
      Net income from continuing operations for the three months ended June 30, 2024 was $4.8 million compared to net loss of $20.2 million for the prior year period.

      Adjusted EBITDA:
      Adjusted EBITDA1 increased 87%to $4.9 million for the three months ended June 30, 2024 compared to $2.6 million for the prior year quarter.

      Fiscal Q2 2025 Expectations:
      We expect to see continued strong net revenue and adjusted gross margins across our cannabis business, supported by net revenue1 growth in Europe and Australia.

      For plant propagation, we expect to see seasonally reduced revenues and gross profit in Q2 2025 that will be in line with historical performance as 25% – 35% of revenues are normally earned in the second half of a calendar year.

      Positive adjusted EBITDA is expected to continue while free cash flow is anticipated to be negatively impacted by several significant annual and one-time cash payments that typically occur in Q2 2025.

      Key Quarterly Financial Results


      Three months ended

      ($ thousands, except Operational Results)

      June 30,
      2024

      March 31,
      2024(4)

      $ Change

      % Change

      June 30,
      2023(4)

      $ Change

      % Change

      Financial Results








      Net revenue (1)(2a)

      $83,435

      $67,411

      $16,024

      24 %

      $74,732

      $8,703

      12 %

      Medical cannabis net revenue (1)(2a)

      $47,201

      $45,648

      $1,553

      3 %

      $41,615

      $5,586

      13 %

      Consumer cannabis net revenue (1)(2a)

      $11,533

      $10,233

      $1,300

      13 %

      $12,842

      ($1,309)

      (10 %)

      Plant propagation revenue

      $23,081

      $10,416

      $12,665

      122 %

      $19,904

      $3,177

      16 %

      Adjusted gross margin before FV adjustments on total net








      revenue (2b)

      43 %

      50 %

      N/A

      (7 %)

      44 %

      N/A

      (1 %)

      Adjusted gross margin before FV adjustments on cannabis








      net revenue (2b)

      53 %

      54 %

      N/A

      (1 %)

      52 %

      N/A

      1 %

      Adjusted gross margin before FV adjustments on medical








      cannabis net revenue (2b)

      69 %

      66 %

      N/A

      3 %

      61 %

      N/A

      8 %

      Adjusted gross margin before FV adjustments on








      consumer cannabis net revenue (2b)

      24 %

      16 %

      N/A

      8 %

      26 %

      N/A

      (2 %)

      Adjusted gross margin before FV adjustments on plant propagation net revenue (2b)

      18 %

      25 %

      N/A

      (7 %)

      22 %

      N/A

      (4 %)

      Adjusted SG&A expense(2d)

      $31,396

      $31,351

      $45

      0 %

      $29,033

      $2,363

      8 %

      Adjusted EBITDA (2c)

      $4,887

      $2,319

      $2,568

      111 %

      $2,619

      $2,268

      87 %

      Free cash flow (2e)

      $6,490

      ($21,866)

      $28,356

      (130 %)

      ($11,686)

      $18,176

      (156 %)

      Balance Sheet








      Working capital (2f)

      $322,563

      $301,985

      $20,578

      7 %

      $192,201

      $130,362

      68 %

      Cannabis inventory and biological assets (3)

      $173,197

      $148,112

      ($62,672)

      (42 %)

      $100,846

      ($15,406)

      (15) %

      Total assets

      $838,689

      $838,673

      $16

      0 %

      $832,188

      $6,501

      1 %

      (1)

      Includes the impact of actual and expected product returns and price adjustments (Q1 2025 – nil; Q1 2024 - $0.6 million Q4 2024 – nil).

      (2)

      These terms are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. Refer to the following sections for reconciliation of Non-GAAP Measures to the IFRS equivalent measure:


      a.

      Refer to the "Revenue" and "Cost of Sales and Gross Margin" section for a reconciliation of cannabis net revenue to the IFRS equivalent.


      b.

      Refer to the "Adjusted Gross Margin" section for reconciliation to the IFRS equivalent.


      c.

      Refer to the "Adjusted EBITDA" section for reconciliation to the IFRS equivalent.


      d.

      Refer to the "Operating Expenses" section for reconciliation to the IFRS equivalent.


      e.

      Refer to the "Liquidity and Capital Resources" section for a reconciliation to the IFRS equivalent.


      f.

      "Working capital" is defined as Current Assets less Current Liabilities as reported on the Company's Consolidated Statements of Financial Position.

      (3)

      Represents total biological assets and inventory, exclusive of merchandise, accessories, supplies, consumables and plant propagation biological assets.

      (4)

      Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations.

      Conference Call

      Aurora will host a conference call today, Wednesday, August 7, 2024, to discuss these results. Miguel Martin, Chief Executive Officer, and Simona King, Chief Financial Officer, will host the call starting at 8:00 a.m. Eastern time | 6:00 a.m. Mountain Time. A question and answer session will follow management's presentation.

      DATE:

      Wednesday, August 7, 2024

      TIME:

      8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time

      WEBCAST:

      Click Here

      This weblink has also been posted to the Company's "Investor Info" link at https://www.auroramj.com/investors/ under "Events".

      About Aurora Cannabis

      Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

      Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

      Forward Looking Statements

      This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the  Company's Q1 FY2025 results, statements under the heading "Fiscal Q2 2025 Expectations", including  as related to net cannabis revenue growth and adjusted gross margins, revenue and gross profit in the plant propagation segment, and expectations for positive adjusted EBITDA and free cash flow, statements regarding the Company's continued commitment to operational excellence and strategic growth, sustained positive momentum, and expectations for SG&A and R&D expenses, as well as those statements regarding the Company's conference call to discuss results.

      These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and nongovernment consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

      The Company's AIF, MD&A and annual financial statements, which have been filed on SEDAR+ and with the SEC, are also available on the Company's website www.auroramj.com and shareholders may receive hard copies free of charge upon request by contacting [email protected].

      Non-GAAP Measures

      This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the Company's management's discussion and analysis for the fiscal period ended June 30, 2024 (the "MD&A") is incorporated by reference into this news release. The MD&A is available on the Company's issuer profiles on SEDAR+ at www.sedarplus.com and on the SEC's EDGAR website at www.sec.gov.

      Net Revenue, Adjusted Gross Profit and Margin

      Net revenue, adjusted gross profit before FV adjustments, and adjusted gross margin before FV adjustments are Non-GAAP Measures and can be reconciled with revenue, gross profit and gross margin, the most directly comparable GAAP financial measures, respectively, as follows:

      ($ thousands)

      Medical
      Cannabis

      Consumer
      Cannabis

      Wholesale

      Bulk Cannabis

      Total
      Cannabis

      Plant
      Propagation

      Total

      Three months ended June 30, 2024







      Gross revenue

      50,121

      17,215

      1,620

      68,956

      23,081

      92,037

      Excise taxes

      (2,920)

      (5,682)

      —

      (8,602)

      —

      (8,602)

      Net revenue (1)

      47,201

      11,533

      1,620

      60,354

      23,081

      83,435

      Non-recurring net revenue adjustments (2)(4)(5)

      —

      —

      —

      —

      (369)

      (369)

      Adjusted net revenue

      47,201

      11,533

      1,620

      60,354

      22,712

      83,066

      Cost of sales

      (16,902)

      (10,557)

      (6,212)

      (33,671)

      (19,639)

      (53,310)

      Depreciation

      1,705

      1,041

      612

      3,358

      1,022

      4,380

      Inventory impairment and non-recurring costs included in







      cost of sales (2)(5)

      800

      733

      431

      1,964

      (118)

      1,846

      Adjusted gross profit (loss) before FV adjustments (1)

      32,804

      2,750

      (3,549)

      32,005

      3,977

      35,982

      Adjusted gross margin before FV adjustments (1)

      69 %

      24 %

      (219 %)

      53 %

      18 %

      43 %

      Three months ended March 31, 2024(7)







      Gross revenue

      48,466

      15,240

      1,114

      64,820

      10,416

      75,236

      Excise taxes

      (2,818)

      (5,007)

      —

      (7,825)

      —

      (7,825)

      Net revenue(1)

      45,648

      10,233

      1,114

      56,995

      10,416

      67,411

      Non-recurring revenue adjustments (4,5)

      —

      —

      —

      —

      $         (192)

      (192)

      Adjusted net revenue

      45,648

      10,233

      1,114

      56,995

      10,224

      67,219

      Cost of sales

      (20,795)

      (11,682)

      (2,686)

      (35,163)

      (8,327)

      (43,490)

      Depreciation

      2,262

      1,195

      284

      3,741

      660

      4,401

      Inventory impairment, non-recurring, out-of-period, and







      market development costs included in cost of sales (2)(3)(4)(5)(6)

      2,985

      1,842

      438

      5,265

      42

      5,307

      Adjusted gross profit (loss) before FV adjustments (1)

      30,100

      1,588

      (850)

      30,838

      2,599

      33,437

      Adjusted gross margin before FV adjustments (1)

      66 %

      16 %

      (76 %)

      54 %

      25 %

      50 %

      Three months ended June 30, 2023(7)







      Gross revenue

      43,872

      17,051

      371

      61,294

      19,904

      81,198

      Excise taxes

      (2,257)

      (4,209)

      —

      (6,466)

      —

      (6,466)

      Net revenue(1)

      41,615

      12,842

      371

      54,828

      19,904

      74,732

      Non-recurring net revenue adjustments (4)

      (598)

      (249)

      —

      (847)

      —

      (847)

      Adjusted net revenue

      41,017

      12,593

      371

      53,981

      19,904

      73,885

      Cost of sales

      (24,390)

      (15,970)

      (822)

      (41,182)

      (18,951)

      (60,133)

      Depreciation

      2,776

      1,643

      85

      4,504

      870

      5,374

      Inventory impairment, and non-recurring adjustments







      included in cost of sales (2)(4)(5)

      5,692

      5,010

      242

      10,944

      2,501

      13,445

      Adjusted gross profit (loss) before FV adjustments (1)

      25,095

      3,276

      (124)

      28,247

      4,324

      32,571

      Adjusted gross margin before FV adjustments (1)

      61 %

      26 %

      (33 %)

      52 %

      22 %

      44 %

      (1)

      These terms are Non-GAAP Measures and are note recognized, defined or standardized measures under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A.

      (2)

      Inventory impairment includes inventory write-downs due to lower of cost or net realizable value adjustments, obsolescence provision adjustments, and inventory destruction.

      (3)

      Markets under development represents the adjustment for business operations focused on developing international markets prior to commercialization.

      (4)

      Non-recurring items includes inventory count adjustments resulting from facility shutdowns and abnormal fluctuations in utilities costs in the plant propagation business.

      (5)

      Non-recurring items includes business transformation costs in connection with the re-purposing and ramp-up of the Company's Sky and Sun facilities.

      (6)

      Out-of-period adjustments include adjustments to input assumptions related to fair value of biological assets.

      (7)

      Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations.

      Adjusted EBITDA

      Adjusted EBITDA is a Non-GAAP Measure and can be reconciled with net income (loss), the most directly comparable GAAP financial measure, as follows:


      Three months ended 

      ($ thousands)

      June 30, 2024

      March 31, 2024

      June 30, 2023

      Net income (loss) from continuing operations

      4,844

      (20,267)

      (20,197)

      Income tax expense (recovery)

      2,857

      (711)

      96

      Other income (expense)

      (6,824)

      18,719

      5,680

      Share-based compensation

      3,019

      3,029

      2,281

      Depreciation and amortization

      6,494

      6,296

      8,241

      Acquisition costs

      1,001

      2,970

      226

      Inventory and biological assets fair value and impairment adjustments

      (12,348)

      (16,940)

      (3,404)

      Business transformation related charges (1)

      4,381

      7,539

      5,717

      Out-of-period adjustments (2)

      —

      (185)

      330

      Non-recurring items (3)

      1,463

      1,869

      3,649

      Adjusted EBITDA (4)

      4,887

      2,319

      2,619

      (1)

      Business transformation related charges includes costs related to closed facilities, certain IT project costs, costs associated with the repurposing of Sky, severance and retention costs in connection with the business transformation plan, costs associated with the retention of certain medical aggregators. Some prior period amounts have been adjusted for changes in presentation.

      (2)

      Out-of-period adjustments reflect adjustments to net loss for the financial impact of transactions recorded in the current period that relate to prior periods. Some prior period amounts have been adjusted for changes in presentation.

      (3)

      Non-recurring items includes one-time excise tax refunds, non-core adjusted wholesale bulk margins, inventory count adjustments resulting from facility shutdowns and inter-site transfers, litigation and non-recurring project costs.

      (4)

      Adjusted EBITDA is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the MD&A. Prior period comparatives were adjusted to include the adjustments for markets under development, business transformation costs, and non-recurring charges related to non-core bulk cannabis wholesales to be comparable to the current period presentation.

      Adjusted SG&A

      Adjusted SG&A is a Non-GAAP Measure and can be reconciled with sales and marketing and general and administrative expenses, the most directly comparable GAAP financial measure, as follows: 


      Three months ended

      ($ thousands) 

      June 20, 2024

      March 31, 2024

      June 30, 2023

      Sales and marketing

      14,024

      14,530

      12,670

      General and administration

      22,524

      25,418

      21,349

      Business transformation costs

      (4,868)

      (6,862)

      (4,063)

      Out-of-period adjustments

      —

      (642)

      (330)

      Non-recurring costs

      (284)

      (1,093)

      (593)

      Adjusted SG&A (1)

      31,396

      31,351

      29,033

      (1)

      Adjusted SG&A is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A.

      (2)

      Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations.

      Free Cash Flow

      The table below outlines free cash flow for the periods ended:


      Three months ended

      ($ thousands)

      June 30, 2024

      March 31, 2024(2)

      June 30, 2023(2)

      Cash used in operating activities from continuing operations before changes in non- cash working capital

      (1,822)

      (10,074)

      (13,005)

      Changes in non-cash working capital

      10,682

      (10,335)

      3,814

      Net cash provided by (used in) operating activities from continuing operations

      8,860

      (20,409)

      (9,191)

      Less: maintenance capital expenditures(1)

      (2,370)

      (1,457)

      (2,495)

      Free cash flow(1)

      6,490

      (21,866)

      (11,686)

      (1)

      Maintenance capital expenditures are comprised of costs to sustain facilities, machinery and equipment in working order to support operations and excludes discretionary investments for revenue growth.

      (2)

      Free cash flow is a Non-GAAP Measure and is not a recognized, defined, or a standardized measure under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A.

      Working Capital

      Working capital is a Non-GAAP Measure and can be reconciled with total current assets and total current liabilities, the most directly comparable GAAP financial measure, as follows:


      Three months ended 

      ($ thousands)

      June 30, 2024

      March 31, 2024

      June 30, 2023

      Total current assets

      439,366

      426,605

      399,311

      Total current liabilities

      (116,803)

      (124,620)

      (207,110)

      Working capital(1)

      322,563

      301,985

      192,201

      (1)

      Working capital for the three months ended March 31, 2024 and June 30, 2023 has been adjusted. Refer to discussion under "Liquidity and Capital Resources" section of the MD&A.

      SOURCE Aurora Cannabis Inc.

      Modal title

      Also from this source

      Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program

      Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program

      Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, today shared...

      Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside

      Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside

      Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the Canadian-based leading global medical cannabis company, today...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Cannabis

      Cannabis

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.